Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENOCARE: Genotype-Guided Dosing of Irinotecan in Pancreatic and Colorectal Cancer
NCT05391126Recruiting
- Start
- Sep 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of irinotecan in pancreatic cancer (PC) and colorectal cancer (CRC) (2 arms). Primary endpoint: Adverse Events Frequency at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
irinotecan
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05391126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391126.